

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
August 5, 2020
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 5, 2020.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Divya Ahuja, MD
Kimberly Rudd, MD
Cheryl Hartvigsen, RPh
Erika Tillery, PharmD

Edward Behling, MD
Kenric Ware, PharmD
Kelli Savia, DO
Kashyap Patel, MD

Jony Bolinger, MD
Thomas Phillips, RPh
Gregory Browning, MD

SC DHHS Staff:

Jim Bradford, MD
William Wynn, PharmD
Byron Roberts, JD
Janet Giles
Michael Psikogios, MD
Ashley Sirianni, DNP, FNP-BC

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 6, 2020

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class

- No Speakers

C. Drug Classes for Review

Classes for Re-Review

- Anticoagulants (Injectable)
- SGLT2 Inhibitors
- Alpha Glucosidase Inhibitors (Oral)
- Beta Blockers (Oral)
- Xanthine Oxidase Inhibitors (Oral)
- Electrolyte Depleters (Phosphate Binders) (Oral)

The chart below represents the recommendations from the P & T Committee:

ANTICOAGULANTS (Injectable)	
Preferred	Non-Preferred
Enoxaparin Sodium	Arixtra ⁺
	Fragmin ⁺
	Lovenox
SGLT2 INHIBITORS	
Preferred	Non-Preferred
Farxiga	Invokamet XR
Invokana	Synjardy
Invokamet	Synjardy XR
Jardiance [‡]	Steglatro
	Segluromet
	Trajardy XR
	Xigduo XR ⁺
ALPHA GLUCOSIDASE INHIBITORS	
Preferred	Non-Preferred
Acarbose	Glyset ⁺
	Precose

BETA BLOCKERS	
Preferred	Non-Preferred
Acebutolol	Betapace/AF
Atenolol	Betaxolol ⁺
Atenolol/Chlorthal	Bystolic
Bisoprolol Fumarate	Coreg/CR
Bisoprolol/HCT	Corgard
Carvedilol IR	Dutoprolol
Labetalol	Hemangeol
Metoprolol succ SR‡	Inderal LA/XL
Metoprolol Tartrate	Innopran XL
Nadolol	Kaspargo
Propranolol IR/ER	Levatolol
Propranolol HCT	Lopressor/HCTZ
Sotalol/AF	Pindolol ⁺
	Sorine
	Sotylize
	Tenormin/Tenoretic
	Toprol XL
	Timolol ⁺
	Ziac
XANTHINE OXIDASE INIBITORS/ANTHYPERURICEMICS	
Preferred	Non-Preferred
Allopurinol	Colchicine cap
Colcrys tab‡	Colchicine tab
Mitigare	Febuxostat
Probenecid	Gloperba
Probenecid/colchicine	Uloric
	Zyloprim
ELETROLYTE DEPLETERS (PHOSPHATE BINDERS) (ORAL)	
Preferred	Non-Preferred
Calcium acetate cap	Auryxia
Calcium acetate tab‡	Calphron
Sevelamer carbonate‡	Eliphos
	Ferric citrate
	Foxrenol pwr packet/chew tab ⁺
	Lanthanum carb chew tab
	Phoslyra
	Renagel ⁺
	Renvela ⁺
	Velphoro

‡ Added as “Preferred”

+ Moved to “Non-Preferred”

5. **Old Business**

None

6. **New Business**

Lisa presented new drugs to market. William updated the Committee on PDL, effective August 1, 2020, where brands moved to generic. He provided an overview of the process for Pharma meetings which will continue in 2021. The SC DHHS website offers COVID19 information addressing the needs of providers and members. In addition, William provided updates on items that were implemented in July 2020. Effective July 1, 2020, SC DHHS (1) adopted CMS standard list of HCPCS codes for MAT, (2) implemented 12 month supply of systemic birth control if written by the prescriber and (3) HCV carved back in to the MCOs. Effective July 15, 2020, payment algorithm updated to include NADAC + \$10.50 dispensing fee. SC DHHS currently developing AAC pricing with Mercer with a proposed implementation date of November 2, 2020. William did share that the agency has a new Deputy Director, Janelle Smith. In closing, William advised he is reviewing P&T Committee by-laws and will forward them to the Committee for review/discussion during the next meeting on November 4, 2020.

7. **Resolved Items**

Classes for Re-Review

- Anticoagulants (Injectable)
- SGLT2 Inhibitors
- Alpha Glucosidase Inhibitors (Oral)
- Beta Blockers (Oral)
- Xanthine Oxidase Inhibitors (Oral)
- Electrolyte Depleters (Phosphate Binders) (Oral)

8. **Closing Comments**

The next meeting will be held Wednesday, November 4, 2020.

9. **Adjournment**

The meeting adjourned at 5:05 p.m.